Fig. 2From: A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPDPatient disposition. BID Twice daily, GP Glycopyrronium, MDI Metered dose inhaler, QID Four times dailyBack to article page